Dec 10, 2019: Daiichi Sankyo Company, Limited announced  that the first patient has been dosed in a pivotal phase 2 study in Japan evaluating  valemetostat (DS-3201), an investigational EZH1/2 dual inhibitor, in patients with relapsed/refractory adult T-cell leukemia-lymphoma (ATL). (non-Hodgkin’s lymphoma).
Patients often face a difficult prognosis, especially for relapsed disease while treatment with ATL. Valemetostat is a novel targeted therapy that has demonstrated initial potential in several types of NHL including ATL, which represents one of the greatest areas of need among lymphoma patients, mainly in Japan.
The pivotal, open-label, multi-center, single-arm phase 2 study will evaluate efficacy and safety of valemetostat as monotherapy in patients with relapsed/refractory ATL.
It is an investigational and potential first-in-class EZH1/2 dual inhibitor that targets epigenetic regulation by inhibiting both the EZH1 (enhancer of zeste homolog 1) and EZH2 (enhancer of zeste homolog 2) enzymes, which act through histone methylation to regulate gene expression. https://www.daiichisankyo.com/media_investors/media_relations/press_releases/detail/007080.html
